This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Harbour_BioMed appoints Dhavalkumar_Patel
Business appointment

Harbour_BioMed appoints Dhavalkumar_Patel

Analysis based on 7 articles · First reported Jun 12, 2026 · Last updated Jun 12, 2026

Sentiment
40
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The appointment of Dhavalkumar Patel>>> as Scientific Advisor is expected to positively impact Harbour BioMed>>>'s stock price due to his extensive experience and proven track record in drug development. This move signals a strengthened commitment to advancing its immunology pipeline, potentially leading to future breakthroughs and increased market valuation for Harbour BioMed>>>.

biotechnology pharmaceuticals
Event Summary

Harbour BioMed>>> announced the appointment of Dhavalkumar Patel>>> as a Scientific Advisor. Dhavalkumar Patel>>> brings over two decades of experience in therapeutic innovation from roles at Sana Biotechnology>>>, EITC>>>, and Novartis>>>. His expertise is expected to significantly contribute to Harbour BioMed>>>'s immunology pipeline and overall drug development strategy. Jingsong Wang>>>, CEO of Harbour BioMed>>>, highlighted Dhavalkumar Patel>>>'s deep immunological science and strategic insight as a tremendous asset.

Entities Involved
priv
Harbour BioMed
Harbour BioMed appointed Dhavalkumar Patel>>> as a Scientific Advisor, which is expected to enhance its immunology pipeline and drug development capabilities.
Importance 100.0 Sentiment 40.0
per
Dhavalkumar Patel
Dhavalkumar Patel>>> was appointed Scientific Advisor to Harbour BioMed>>>, bringing extensive experience in therapeutic innovation and drug development to the company.
Importance 90.0 Sentiment 50.0
stock
Sana Biotechnology
Dhavalkumar Patel>>> is currently Executive Vice President and Chief Scientific Officer of Sana Biotechnology>>>.
Importance 20.0 Sentiment 0.0
per
Jingsong Wang
Jingsong Wang>>>, CEO of Harbour BioMed>>>, expressed enthusiasm for Dhavalkumar Patel>>>'s appointment.
Importance 10.0 Sentiment 0.0
stock
EITC
Dhavalkumar Patel>>> previously served as Executive Vice President and Chief Scientific Officer of EITC>>>.
Importance 10.0 Sentiment 0.0
stock
Novartis
Dhavalkumar Patel>>> spent 10 years at Novartis>>> as Head of Research for NIBR Europe.
Importance 10.0 Sentiment 0.0
priv
Inflazome
Dhavalkumar Patel>>> served on the Board of Directors for Inflazome>>> prior to its acquisition by Roche.
Importance 5.0 Sentiment 0.0
oth
Priothera
Dhavalkumar Patel>>> currently serves on the Board of Directors for Priothera>>>.
Importance 5.0 Sentiment 0.0
priv
Quell Therapeutics
Dhavalkumar Patel>>> currently serves on the Board of Directors for Quell Therapeutics>>>.
Importance 5.0 Sentiment 0.0
priv
RE-AIM Therapeutics
Dhavalkumar Patel>>> currently serves on the Board of Directors for RE-AIM Therapeutics>>>.
Importance 5.0 Sentiment 0.0
priv
Mimetas BV
Dhavalkumar Patel>>> serves as Chair of the Board of Directors for Mimetas BV>>>.
Importance 5.0 Sentiment 0.0
stock
Roche
Roche>>> acquired Inflazome>>> in 2020.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.